
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report: **December 16, 2009**

Corgenix Medical Corporation

(Exact Name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of incorporation)

000-24541
(Commission File Number)

93-1223466
(I.R.S. Employer
Identification No.)

11575 Main Street, Number 400
Broomfield, Colorado 80020
(Address, including zip code, of principal executive offices)

(303) 457-4345
(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting Material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 7.01 Regulation FD Disclosure

On December 15, 2009, Corgenix Medical Corporation management met with shareholders at its annual shareholders meeting. A copy of the presentation materials of the company's President and Chief Executive Officer and Chief Financial Officer that were used at that meeting is filed as Exhibit 99.1 hereto.

ITEM 8.01 Other Events

The 2009 annual meeting of the shareholders of Corgenix Medical Corporation was held at the company's corporate offices on December 15, 2009 at approximately 9:00 a.m. Mountain Standard Time. At the meeting, the shareholders elected Dr. Luis R. Lopez, Mr. Douglass T. Simpson, Mr. Robert Tutag, Mr. C. David Kikumoto, Mr. Larry G. Rau, Mr. Dennis Walczewski and Mr. Stephen P. Gouze as directors of the company and ratified the appointment of Hein & Associates LLP as the company's independent public accountants for the fiscal year ending June 30, 2010. The company will disclose the voting detail regarding the proposals approved at the meeting in its upcoming annual filing.

ITEM 9.01 Financial Statements and Exhibits

- a) Not applicable.
- b) Not applicable.
- c) Not applicable.
- d) Exhibits:

99.1 Shareholder presentation material of the President and Chief Executive Officer and Chief Financial Officer of Corgenix Medical Corporation used on December 15, 2009.

Safe Harbor Statement

Statements in this report that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this report are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORGENIX MEDICAL CORPORATION

Date: December 16, 2009

By: /s/ Douglass T. Simpson
Douglass T. Simpson, President and Chief Executive Officer

Corgenix Medical Corporation
 Annual Shareholder Meeting
 December 16, 2008
 PowerPoint Presentation

Slide 1 – Title Slide

*Annual Meeting of the Shareholders
 December 15, 2009*

Slide 2 – Agenda

- Review of Corporate Goals
- Revenue Strategies
- Review of Fiscal Year 2009
 - Financials
 - Key Events, Achievements and Disappointments
- Fiscal Year 2010 Goals
- Review of Fiscal Year 2010 Year-to-Date Results
- Plan for 2011-2012

Slide 3 – Corporate Goals

- Financial Strength
- Consistent Growth in Revenues and Profitability
- Continued Improvement in Shareholder Liquidity
- Product Quality

Slide 4 - Revenue Strategies

- Base business Products
 - Anti-phospholipids
 - Vascular Diseases
 - Hyaluronic Acid
 - Autoimmune
- Growth Opportunity Products
 - AspirinWorks
 - AtherOx
 - Viruses and Bio-defense
- Contract development and manufacturing

Slide 5 – Strategic Alliances

- (logos of strategic alliance companies)

Slide 6 - FY 2009 and FY 2010 YTD Summary Statements of Operations

	<u>FY 2010</u>	<u>FY 2009</u>	<u>FY 2010</u>	<u>FY 2009</u>
	<u>3-mo</u>	<u>3-mo</u>	<u>FY ended</u>	<u>FY ended</u>
	<u>ended</u>	<u>ended</u>	<u>6/30/09</u>	<u>6/30/08</u>
	<u>9/30/09</u>	<u>9/30/08</u>	<u>(Audited)</u>	<u>(Audited)</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>		
Sales.....	\$ 2,045	\$ 2,002	\$ 8,063	\$ 8,366
Gross Profit.....	\$ 1,116	\$ 1,107	\$ 4,482	\$ 4,337
Operating Expenses.....	\$ 1,031	\$ 1,201	\$ 4,831	\$ 4,939
Operating Income (Loss).....	\$ 84	\$ (94)	\$ (349)	\$ (602)
Net Loss.....	\$ (7)	\$ (341)	\$ (1,571)	\$ (2,112)

Slide 7 - FY 2009 and FY 2010 YTD Summary Balance Sheets

	At September 30, 2009	At June 30, 2009	At June 30, 2008
	(Unaudited)	(Audited)	(Audited)
Cash	\$ 982	\$ 785	\$ 1,520
Working Capital.....	\$ 2,195	\$ 2,013	\$ 2,889
Long Term Debt.....	\$ 753	\$ 744	\$ 1,276
Stockholder's Equity	\$ 3,152	\$ 3,113	\$ 4,153

Slide 8 – FY 2009 – Key Events of the Year

- July 2008
 - Announcement of expansion of Hemorrhagic Fever Virus program
 - Established AspirinWorks collaboration with SpectraCell Laboratories, a major clinical testing lab focusing on cardiovascular testing
- August 2008
 - Established collaboration with BG Medicine to study role of AtherOx technology products in cardiac risk assessment
- September 2008
 - Third U.S. patent issued for AtherOx technology
- October 2008
 - CHARISMA study published – prospective study confirms elevated levels of 11dhTxB2 indicate increased risk of heart attack, stroke and cardiac death

Slide 9 – FY 2009 Key Events of the Year

- January 2009
 - Announced two additional AtherOx patents (one in the U.S. and one in the EU), bringing the total number of AtherOx patents issued to five (5)
 - Announced a new collaboration with Battelle for bio-defense related products
- March 2009
 - Publication of POLYCAP study which included AspirinWorks
 - Initial phase of debt restructure
- May 2009
 - Announcement of second major NIH grant to study Lassa fever

Slide 10 – FY 2009 Accomplishments

- Improvement in Cost of Goods Sold
- 2.2% reduction in Operating Expenses
- Operating loss decreased 42%
- Interest expense decreased 15.8%
- Net loss decreased 25.7%
- EBITDA increased almost 400% to \$404,000
- Strengthened our patent position
- Major advancement in several important strategic programs
- Expanded US and international distribution network

Slide 11 – FY 2009 Disappointments

- Revenue declined 3.6% over prior year
- Reduction in operating expenses, given level of sales, still insufficient to achieve profitability
- Reduction in sales to one contract manufacturing customer impacted revenues in first half of FY 2009
- AspirinWorks business growing but slower than original expectations

Slide 12 – FY 2010 Goals

- Return to positive revenue growth
- Continued improvement in operating income, EBITDA, and overall financial strength
- Keep operating expenses under control
- Build foundation of market for AspirinWorks and generate meaningful revenue
- Advance science of AtherOx and prepare for next FDA 510(k) filing
- Continue progress of viral program and launch first products
- Enhance contract manufacturing business with new strategic alliances

Slide 13 – FY 2010 YTD Key Events of the Year

- July 2009
 - American Medical Association (AMA) establishes new CPT code for reimbursement of AspirinWorks
- October 2009
 - Announced securing \$1.75 million asset based credit facility to further restructure debt
- December 2009
 - Fully retired convertible debt from 2005 and 2006 financings
 - Announced new contract manufacturing agreement with BG Medicine

Slide 14 - FY 2010 YTD Accomplishments

- On pace for a record sales year
- Expenses under control
- New CPT code for AspirinWorks
- Had a solid first quarter
 - Revenue grew 2.2% over prior year
 - 14% reduction in Operating Expenses
 - 73% reduction in interest expense
 - Doubling of EBITDA to \$181,000
 - Further restructured debt

Slide 15 – FY 2010 YTD Disappointments

- Ramp up of AspirinWorks revenue still lagging behind original projections
- The medical products industry as a whole has not fully recovered from the difficult economy although we are seeing improvement

Slide 16 – Plan for FY 2011 and FY 2012

- Return to double digit revenue growth via accelerated growth from new products
- Accelerate new product clearances from the FDA
- Expand contract manufacturing business
- Achieve positive and continuously improving operating income and EBITDA
- Enhance shareholder value
- Build on strategic partnerships
- Maintain superior quality system to ensure full regulatory compliance
- Expand delivery technology capabilities